Alnylam (ALNY) Q3 2023: Collaboration Revenue Surges $400M as ATTR Franchise Expands

2023-11-02 | By EarningsIQ Research

Alnylam’s third quarter was defined by a dramatic $400 million increase in collaboration revenue, robust double-digit growth in both TTR and ultra-rare franchises, and a strategic pivot following the FDA’s refusal to approve Patisiran for cardiomyopathy. Management’s focus now centers on the pivotal Helios-B readout in early 2024, which will determine the next phase of franchise expansion and commercial strategy.

Summary

• Collaboration Revenue Inflection: Roche and Regeneron partnerships drove an unprecedented one-time revenue spike.
• ATTR Franchise Realignment: U.S. Ambutra launch accelerated patient conversion, but FDA setback shifts near-term growth bets to Helios-B.
• Pipeline Momentum: Zalvisiran and ALN-APP clinical updates reinforce Alnylam’s RNAi innovation platform ahead of critical 2024 catalysts.

Business Overview

Alnylam Pharmaceuticals develops and commercializes RNA interference (RNAi) therapeutics, a drug class that silences disease-causing genes. The company generates revenue through direct product sales in two major areas—TTR amyloidosis (Onpattro, Amvuttra) and ultra-rare diseases (Givlaari, Oxlumo)—as well as through strategic collaborations, partnerships, and royalties. Its business model combines organic product engine innovation with external R&D and commercialization alliances, aiming for leadership in rare and specialty indications.

Performance Analysis

Alnylam delivered a standout financial quarter with total product revenues up 35% year-over-year, driven by strong U.S. Ambutra performance and steady patient growth across both TTR and ultra-rare portfolios. The TTR franchise, now at $230 million in quarterly revenue, saw an 8% sequential patient increase, with more than 80% of U.S. TTR patients transitioned to Amvuttra. Ultra-rare products also advanced, with Oxlumo posting a 19% sales jump quarter-over-quarter.

However, international TTR sales declined 7% sequentially due to price adjustments in Germany, Japanese inventory destocking, and emerging market order timing. The company’s collaboration revenue soared by nearly $400 million, reflecting the full recognition of a $310 million Roche upfront payment and a $100 million Regeneron milestone, though these are non-recurring events. Gross margin contracted 10 points, largely due to a write-off of Onpattro inventory after the FDA’s non-approval for cardiomyopathy, signaling a near-term margin headwind as the portfolio mix shifts.

• U.S. Ambutra Conversion: Over 80% of U.S. TTR patients are now on Amvuttra, highlighting rapid market adoption.
• Collaboration-Driven Profit: Non-GAAP operating profit was achieved for the first time, but sustainability depends on future product growth rather than one-off collaboration payments.
• Onpattro Cannibalization: Onpattro sales are expected to decrease as Amvuttra expands, with 2024 guidance lowered to $200–$225 million for Onpattro.

Alnylam’s cash position improved to $2.4 billion, providing a buffer as the company transitions toward self-sustaining profitability, but future quarters will revert to operating losses without similar collaboration windfalls.

Executive Commentary

Strategic Positioning

1. TTR Franchise Realignment

Alnylam’s TTR franchise is in transition following the FDA’s rejection of Patisiran for cardiomyopathy. The company is now channeling resources into the Helios-B study of vutrisiran, aiming for a label expansion into cardiomyopathy—a much larger addressable market. The U.S. Ambutra launch has been highly successful, with rapid patient uptake and strong physician endorsement, but future growth is now contingent on Helios-B outcomes and subsequent regulatory success.

2. Commercial Execution and Global Expansion

Patient conversion and market access execution have been strong in the U.S., but international growth is challenged by price pressures and inventory dynamics. Recent launches in Spain and Italy complete Amvuttra’s rollout in major markets, with reimbursement secured faster than industry benchmarks. However, the international segment remains exposed to regional pricing and order volatility.

3. Pipeline and Platform Progress

Alnylam’s innovation engine remains productive, with positive clinical updates for Zalvisiran (hypertension) and ALN-APP (Alzheimer’s disease). The company’s CNS and metabolic pipeline, including ALN-KHK for type 2 diabetes, is advancing, and multiple upcoming data readouts could broaden the company’s addressable markets and reinforce its RNAi platform leadership.

4. Collaboration and Capital Allocation

Strategic alliances with Roche and Regeneron delivered a substantial but non-recurring revenue boost, underscoring Alnylam’s ability to monetize pipeline assets through external partnerships. These deals provide near-term capital while de-risking pipeline development, but future financial health will depend more on commercial execution than on further upfront payments.

Key Considerations

Alnylam’s Q3 reflects both commercial momentum and strategic recalibration. The company is balancing near-term operational execution with long-term pipeline bets, especially as the TTR franchise pivots to new indications and geographies.

Key Considerations:

• FDA Setback Reframes Growth Path: The non-approval of Patisiran for cardiomyopathy places heightened importance on the Helios-B vutrisiran readout for future franchise expansion.
• U.S. Market Outpaces International: Domestic growth is robust, but international sales are hampered by price resets and inventory swings, exposing geographic revenue risk.
• Collaboration Revenue Not Recurring: The $400 million collaboration spike is a one-off event, masking underlying operating losses and reinforcing the need for sustainable product growth.
• Operational Leverage from Patient Growth: 8% sequential patient growth across both TTR and ultra-rare franchises demonstrates the scalability of Alnylam’s commercial infrastructure.

Risks

Alnylam’s near-term prospects hinge on the Helios-B study; a negative or ambiguous outcome would significantly limit expansion into cardiomyopathy and dampen commercial momentum. International pricing and inventory volatility introduce further unpredictability. The company’s operating profitability remains dependent on non-recurring collaboration revenue, and gross margin pressure from inventory write-offs could persist as the product mix evolves. Regulatory and competitive pressures in RNAi and rare disease markets also remain material risks.

Forward Outlook

For Q4 2023, Alnylam guided to:

• Net product revenue at the midpoint of its previously issued range
• Collaboration and royalty revenue raised to $575–$625 million for the full year

For full-year 2023, management maintained all other financial guidance and highlighted:

• Helios-B top-line results expected in early 2024, a pivotal event for the TTR franchise
• Upcoming data readouts for ALN-TTR-SCO4 and ALN-KHK before year-end

Management emphasized continued commercial execution, rapid patient conversion, and the importance of pipeline milestones to drive long-term value.

Takeaways

Alnylam’s Q3 underscores both the power and limitations of its hybrid business model, as one-time collaboration revenue temporarily masks underlying operating losses. The company’s future trajectory will be determined by Helios-B results and the ability to sustain commercial momentum in the face of regulatory and market challenges.

• Collaboration Revenue Masks Core Profitability Challenges: The $400 million surge from Roche and Regeneron partnerships is not repeatable, highlighting the need for product-driven earnings growth.
• Helios-B Readout Is the Next Major Catalyst: All eyes are on early 2024, as success would unlock a larger addressable market and validate the TTR franchise’s next growth phase.
• International Volatility and Gross Margin Pressure Warrant Monitoring: Investors should watch for stabilization in non-U.S. markets and the impact of inventory adjustments on margin structure in 2024.

Conclusion

Alnylam’s third quarter showcased commercial strength, pipeline advancement, and strategic agility, but also revealed ongoing dependence on non-recurring collaboration revenue and regulatory outcomes. The company’s long-term value proposition now hinges on the pivotal Helios-B study, with success required to sustain and expand its TTR leadership.

Industry Read-Through

Alnylam’s quarter offers several cross-industry signals for rare disease and RNAi therapeutics players. The rapid U.S. patient conversion for Amvuttra highlights the potential for differentiated product profiles to drive share gains, even in established categories. The FDA’s insistence on outcomes data for label expansion signals a higher regulatory bar for functional endpoints, affecting all late-stage rare disease programs. The volatility in international pricing and inventory underscores the importance of diversified geographic revenue streams. Finally, the one-time windfall from external partnerships demonstrates the capital-raising power of innovative platforms, but also the risk of over-reliance on deal-driven revenue in biotech business models.

ALNY Healthcare Biotechnology Rare Disease RNAi Collaboration Pipeline ATTR